CoChat

A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours

Open access
Kalathur, Madhuri, Toso, Alberto, Chen, Jingjing, Revandkar, Ajinkya, Danzer-Baltzer, Claudia, Guccini, Ilaria, Alajati, Abdullah, Sarti, Manuela, Pinton, Sandra, Brambilla, Lara, Di Mitri, Diletta, Carbone, Giuseppina, Garcia-Escudero, R, Padova, Alessandro, Magnoni, Letizia, Tarditi, Alessia, Maccari, Laura, Malusa, Federico, Kalathur, Ravi Kiran Reddy, A. Pinna, Lorenzo, Cozza, Giorgio, Ruzzene, Maria, Delaleu, Nicolas, Catapano, Carlo V., Frew, Ian J., Alimonti, Andrea · 2015 · Nature Communications
Cited by 44

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Enhancement of cellular senescence in tumours triggers a stable cell growth arrest and activation of an antitumour immune response that can be exploited for cancer therapy. Currently, there are only a limited number of targeted therapies that act by increasing senescence in cancers, but the majority of them are not selective and also target healthy cells. Here we developed a chemogenomic screening to identify compounds that enhance senescence in PTEN-deficient cells without affecting normal cells. By using this approach, we identified casein kinase 2 (CK2) as a pro-senescent target. Mechanistically, we show that Pten loss increases CK2 levels by activating STAT3. CK2 upregulation in Pten null tumours affects the stability of Pml, an essential regulator of senescence. However, CK2 inhibition stabilizes Pml levels enhancing senescence in Pten null tumours. Taken together, our screening strategy has identified a novel STAT3–CK2–PML network that can be targeted for pro-senescence therapy for cancer. It has been proposed that the identification of genes regulating senescence in the absence of PTEN might help develop pro-senescence compounds for the treatment of cancer. Here, the authors use a combination of chemical and shRNA functional screen and identify CK2 as a potential target.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms8227

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 44

Metadata

Authors
Kalathur, M., Toso, A., Chen, J., Revandkar, A., Danzer-Baltzer, C., Guccini, I., Alajati, A., Sarti, M., Pinton, S., Brambilla, L., Di Mitri, D., Carbone, G., Garcia-Escudero, R., Padova, A., Magnoni, L., Tarditi, A., Maccari, L., Malusa, F., Kalathur, R. K. R., A. Pinna, L., Cozza, G., Ruzzene, M., Delaleu, N., Catapano, C. V., Frew, I. J., & Alimonti, A.
Venue
Nature Communications
Published
2015-06-18
Volume
6
Issue
1
Pages
7227-7227
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2271868513
Cited by
44
References
12
FWCI
3.23
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. https://app.cochat.ai/papers/10.1038/ncomms8227
The paper
Kalathur, M., Toso, A., Chen, J., Revandkar, A., Danzer-Baltzer, C., Guccini, I., Alajati, A., Sarti, M., Pinton, S., Brambilla, L., Di Mitri, D., Carbone, G., Garcia-Escudero, R., Padova, A., Magnoni, L., Tarditi, A., Maccari, L., Malusa, F., Kalathur, R. K. R., . . . Alimonti, A. (2015). A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nature Communications. https://doi.org/10.1038/ncomms8227

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.